



# BUILDING VALUABLE COMPANIES WITH UNIVERSITY DISCOVERIES



INVESTOR PRESENTATION  
AIM: TEK, OTCQB: TEKCF  
Nov. 2022  
© 2022 Tekcapital plc  
[tekcapital.com](http://tekcapital.com)

# IMPORTANT NOTICE

By accepting this document, and in consideration for it being made available to such recipient, each recipient agrees to keep strictly confidential the information contained in it and any information otherwise made available by Tekcapital Plc (the "Company"), whether orally or in writing. In the case of a corporate recipient, this presentation may only be disclosed to such of its directors, officers or employees who are required to review it for the purpose of deciding whether to make an investment in the Company. This document has been provided to each recipient at their request, solely for their information, and may not be reproduced, copied, published, distributed or circulated, to any third party, in whole or in part, or published in whole or in part for any purpose, without the express prior consent of the Company. The purpose of this document is solely to provide information to persons who have expressed an interest in investigating the possibility of investing in the Company.

The information contained in this confidential document (the "Presentation") has been prepared and distributed by the Company. It has not been fully verified and is subject to material updating, completion, revision, verification and further amendment. This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000, as amended ("FSMA"). This Presentation does not constitute, and the Company is not making, an offer of transferable securities to the public within the meaning of sections 85B and 102B of FSMA and it is being delivered for information purposes only to a very limited number of persons and companies who are 'qualified investors' within the meaning of section 86(7) of FSMA purchasing as principal or in circumstances under section 86(2) of FSMA, as well as persons who have professional experience in matters relating to investments and who fall within the category of persons set out in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or are high net worth companies within the meaning set out in Article 49 of the Order or are certified sophisticated investors within the meaning set out in Article 50 of the Order or are a "professional client" or an "eligible counterparty" within the meaning of Article 4 (1)(II) and 24(2), (3) and (4), respectively, of Markets in Financial Instruments Directive (Directive 2004/39/EC) ("MiFID") as MiFID is implemented into national law of the relevant EEA state or are otherwise permitted to receive it (together, the "Relevant Persons"). This Presentation is directed only at Relevant Persons and must not be acted on or relied upon by persons who are not Relevant Persons. Any other person who receives this Presentation should not rely or act upon it. By accepting this Presentation and not immediately returning it, the recipient is deemed to represent and warrant that: (i) they are a person who falls within the above description of persons entitled to receive the Presentation; (ii) they have read, agree and will comply with the contents of this notice; and (iii) they will use the information in this document solely for evaluating your possible interest in acquiring securities of the Company.

The securities mentioned herein have not been and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any U.S. State securities laws, and may not be offered or sold in the United States of America or its territories or possessions (the "United States") unless they are registered under the Securities Act or pursuant to an exemption from or in a transaction not subject to the registration requirements of the Securities Act. Neither this Presentation nor any copy of it may be taken or transmitted into the United States, or distributed, directly or indirectly, in the United States, or to any "US person" as defined in Regulation S under the Securities Act of 1933, including US resident corporations or other entities organised under the laws of the United States or any state thereof or non-U.S. branches or agencies of such corporations or entities. This Presentation is not being made available to persons in Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or any other jurisdiction in which it may be unlawful to do so and it should not be delivered or distributed, directly or indirectly, into or within any such jurisdictions.

The information described in this Presentation may contain certain material information that is confidential, price-sensitive and which has not been publically disclosed. By your receipt of this Presentation you recognise and accept that some or all of the information in this Presentation may be "inside information" as defined in Article 7 of the Market Abuse Regulation EU 596/2014 ("MAR"), Section 118C of the FSMA, section 56 of the Criminal Justice Act 1993 ("CJA") and the Disclosure and Transparency Rules ("DTRs") and constitutes a "market sounding" for the purpose of Article 11 of MAR. You recognise and accept that such information is being provided to you by the Company pursuant to Article 11 of MAR and DTR 2.5.7G(2)(b) and you confirm, warrant and undertake that you will not: (i) deal in securities that are price-affected securities (as defined in the CJA) in relation to the inside information, encourage another person to deal in price-affected securities or disclose the information except as permitted by the CJA or MAR or before the inside information is made public; (ii) or cancel or amend an order which has already been placed concerning a financial instrument (as defined in MAR) to which the inside information relates; (iii) deal or

attempt to deal in a qualifying investment or related investment (as defined in MAR) on the basis of the inside information; (iv) disclose the inside information to another person other than in the proper course of the exercise of your employment, profession or duties; or (v) engage in behaviour based on any inside information which might amount to market abuse or market manipulation for the purposes of MAR. Recipients should take their own legal advice on the obligation to which they will be subject and the application of MAR and in particular make their own assessment of whether they are in possession of inside information and when such information ceases to be inside information.

Prospective investors must rely on their own examination of the legal, taxation, financial and other consequences of an investment in the Company, including the merits of investing and the risks involved. Prospective investors should not treat the contents of this Presentation as advice relating to legal, taxation or investment matters and are advised to consult their own professional advisers concerning any acquisition of shares in the Company.

Certain of the information contained in this Presentation has been obtained from published sources prepared by other parties. Certain other information has been extracted from unpublished sources prepared by other parties which have been made available to the Company. The Company has not carried out an independent investigation to verify the accuracy and completeness of such third party information. No responsibility is accepted by the Company or any of its directors, officers, employees or agents for the accuracy or completeness of such information.

All statements of opinion and/or belief contained in this Presentation and all views expressed represent the directors' own current assessment and interpretation of information available to them as at the date of this Presentation. In addition, this Presentation contains certain "forward-looking statements", including but not limited to, the statements regarding the Company's overall objectives and strategic plans, timetables and capital expenditures. Forward-looking statements express, as at the date of this Presentation, the Company's plans, estimates, forecasts, projections, opinions, expectations or beliefs as to future events, results or performance. Forward-looking statements involve a number of risks and uncertainties, many of which are beyond the Company's control, and there can be no assurance that such statements will prove to be accurate. No representation is made or assurance given that such statements or views are correct or that the objectives of the Company will be achieved. The reader is cautioned not to place reliance on these statements or views and no responsibility is accepted by the Company or any of its directors, officers, employees or agents in respect thereof. The Company does not undertake to update any forward-looking statement or other information that is contained in this Presentation. Neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the information contained in this Presentation or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.

Neither the issue of this Presentation nor any part of its contents is to be taken as any form of contract, commitment or recommendation on the part of the Company or the directors of the Company to proceed with any transaction or accept any offer and the right is reserved to terminate any discussions or negotiations with any prospective investors. The Company reserves the right without any notice or liability to the recipient of this Presentation or its advisers to: (i) change any of the procedures, timetable or requirements or terminate negotiations at any time prior to the signing of any binding agreement with investors; (ii) provide different information or access to information to different persons; (iii) agree variations to the property, rights and liabilities comprised in the Company; and (iv) negotiate at the same time with more than one person. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. This Presentation should not be considered a recommendation by the Company or any of its affiliates in relation to any prospective acquisition of shares in the Company. Please be aware that the Company's net asset value and financial results will fluctuate due to a wide variety of Company specific and macro-economic conditions.

No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of the Company or any of its affiliates, any of its directors, officers or employees or any other person as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted for any such information or opinions or for any errors or omissions.

**Further, due to the Covid 19 pandemic, Company results, and net assets may be negatively impacted.**



## TRANSFORMING UNIVERSITY DISCOVERIES INTO VALUABLE NEW PRODUCTS

1

Building portfolio companies with university technology coupled with star power management

2

Providing technology transfer services for 250+ leading universities

3

Multi-year track record of significant growth of net assets and returns on invested capital

*"In addition to a growing portfolio of university IP investments, Tekcapital helps research institutions and businesses develop disruptive technologies and expand their portfolios of intellectual capital." -Julian Mitchell*

**Forbes**

# 2022 H1 FINANCIAL RESULTS

## OBJECTIVE

Grow our Net Assets by building portfolio companies around compelling innovations that can improve people's lives.

## PERFORMANCE

Net Assets increased 13% to US\$76.9m (30 November 2021: US\$68.1m)  
NAV per share \$0.51 (30 Nov 2020: \$0.48)

Total Revenue was US\$8.0m (H1 2021: US\$14.5m)

-Net increase of US\$7.5m in the fair value of portfolio companies  
(H1 2021: US\$13.8m)

-Profit after tax: US\$6.7m (H1 2021: US\$13.0m)

-Diluted EPS \$0.05 (H1 2021: US\$0.12)

# 2022 H1 FINANCIAL RESULTS

KEY FINANCIAL DATA (\$ IN MILLIONS, EXCEPT NAV PER SHARE)

	2022 H1	2021	2020	2019
Total Net Assets	\$76.9	\$68.1	\$32.7	\$22.3
Fair Value of the Portfolio	\$74.3	\$62.5	\$30.5	\$20.3
Total Revenue	\$8.0	\$29.2	\$9.9	\$7.7
After Tax Profit	\$6.7	\$26.4	\$7.7	\$5.5
Net Assets per Share	\$0.51	\$0.48	\$0.35	\$0.35

## NET ASSETS (\$USm)



# TEKCAPITAL'S INVENTION DISCOVERY NETWORK



We have visibility to a large portion of the world's university-developed IP from 4,500 research institutions. This helps mitigate adverse selection and provides continuous acquisition opportunities.



## PORTFOLIO COMPANIES

PERCENTAGE OWNERSHIP & BOOK VALUE AT 31 MAY 2022



Ownership: ~12%  
BV H1 2022: \$18.9m



Ownership: 100%\*  
BV H1 2022: \$27.1m



Ownership: 100%\*\*  
BV H1 2022: \$18.1m



Ownership: 97.2%\*\*\*  
BV H1 2022: \$7.0m

\*Lucyd Ltd owns ~ 71% of Innovative Eyewear Inc. its U.S. based subsidiary.

\*\*Guident Ltd owns ~91% of Guident Corp. its U.S. based subsidiary.

\*\*\*MicroSalt Ltd owns ~72% of MicroSalt Inc, its U.S. based subsidiary.

## Premium Medical Devices at Value Prices

- **Medical device company delivering and developing innovative oxygen therapy products.**
- 30 March 2022 Belluscura executed an agreement with InnoMax Medical Technology to manufacture its X-PLO<sub>2</sub>R portable oxygen concentrator in China, which is expected to more than double its manufacturing capacity and accelerate international expansion.
- 07 April 2022 Belluscura was awarded a Distribution and Pricing Agreement from the United States Defense Logistics Agency for the X-PLO<sub>2</sub>R.
- 3 September 2021 X-PLO<sub>2</sub>R commercially launched with first units leaving production line to customers.
- 24 May 2021 Belluscura announced its IPO on AIM at 45 pence per share. Tek holds 17.1m shares worth approximately \$15m.
- Received FDA clearance for their X-PLO<sub>2</sub>R™ portable oxygen concentrator on 8 March 2021.
- **The Global Oxygen Concentrators is Expected to Reach \$2.92 Billion in 2025.<sup>1</sup>**

## Tekcapital owns ~12% (15.1m shares) of Belluscura plc.

<sup>1</sup> <https://www.globenewswire.com/news-release/2021/11/03/2326359/28124/en/Global-Oxygen-Concentrators-Market-Report-2021-Market-is-Expected-to-Reach-2-92-Billion-in-2025-at-a-CAGR-of-7-8-Forecast-to-2030.html>

## X-PLO<sub>2</sub>R Portable Oxygen Concentrator



### Specifications

- Lightest:** Only 1.25kg (2.8lbs)
- Quiet:** Only 39 dB
- Reliable:** Long battery duration
- Modular:** The first FDA cleared POC with consumer replaceable filter cartridges
- Strong IP:** Through joint development with SDG, Belluscura owns or has exclusively licenced >26 patents and applications in multiple jurisdictions relating to oxygen enrichment devices and treatments.





## Lucyd: the clear choice for smart eyewear

- **Goal: Upgrade your Eyewear®. Develop a successful global smart eyewear brands for prescription and sunglasses for all-day wear.**
- Innovative Eyewear, Inc. completed its IPO and listed on Nasdaq under ticker symbol: LUCY for their common stock and LUCYW for their warrants on 15 August 2022. Post-IPO valuation was approximately \$54m.
- Lucyd smart eyewear is currently sold in >200 retail stores and on numerous ecommerce platforms including Amazon, BestBuy.com, DicksSportingGoods.com, etc.
- Lucyd has 44 patents and applications covering its products.
- **The TAM for eyewear is ~\$140b<sup>1</sup>. The current U.S. market which Innovative Eyewear is focusing on is \$28.3b<sup>2</sup>**

**Tekcapital owns 100% of Lucyd Ltd. & ~71% of Innovative Eyewear Inc.**

1 <https://www.statista.com/statistics/300087/global-eyewear-market-value/>

2 <https://www.statista.com/outlook/cmo/eyewear/united-states>



Lucyd Lyte. The first prescription Bluetooth® powered glasses for all day wear.



 innovative eyewear.



# guident

## Software to enhance safety & efficiency of autonomous vehicles & ground-based delivery devices

- **Goal: Provide managed software solutions for autonomous vehicle manufacturers and operators to enhance their safety. Guident is building a remote monitoring and control center (RMCC) for AV's in Florida and seeks to have it operational in 2021.**
- Guident believes it has developed one of the industry's leading, low latency (< 38 ms) RMCC for teleoperation of vehicle and land-based delivery robots.
- We expect exponential AV market growth and the need for Low-latency teleoperation to enhance safety.


**Tekcapital owns 100% of Guident Ltd.**

- **14 Nov 2022 Guident selected to provide autonomous shuttle services for Boca Raton Innovation Campus (BRiC)**
- 5 May 2022 Guident wins bid from Jacksonville, Florida Transportation Authority to provide its remote monitoring and control services for municipal autonomous vehicles.
- 3 May 2022 Guident announced it is working with Airspan Networks to provide customers with connectivity and software for AV's using CBRS (Citizens Broadband Radio Service) spectrum
- 19 April 2022 Perrone Robotics, Inc. and Guident Corp. Sign Strategic Alliance
- **The market for last mile fully autonomous delivery vehicles is projected to reach US \$11 billion in 2021<sup>1</sup>.**



<sup>1</sup> <https://www.alliedmarketresearch.com/autonomous-last-mile-delivery-market>

## Boca Raton Innovation Campus & Shuttle Map



# guident

## Regenerative Shock Absorbers



# MICROSALT®

## Patented Low-sodium salt (MicroSalt®)

- Salarius aims to make a dent in cardiovascular disease by providing the best, great tasting low-sodium salt that is all natural, non-GMO and Kosher
- Goal: Become the leading , all natural, low-sodium salt supplier
- MicroSalt receives the Sodium Reduction Technology Provider of the Year Award for 2022.
- SaltMe! Chips are now being sold in ~2200 Kroger supermarkets and hundreds of other specialty stores in the U.S.
- The global salt substitute market is expected to grow from US\$1.2 billion in 2021 to US\$ 2.3 billion by 2030, at a CAGR of 7.9% during the forecast period 2022-2030. <sup>1</sup>

**Tekcapital owns 97.2% of Salarius Ltd.**  
**MicroSalt Ltd owns ~73% of Microsalt Inc, its U.S.subsidiary**

**Initial MicroSalt® Applications**

**Saltshakers  
Snacks &  
Ready-to-eat meals**



**50% LESS SODIUM**  
Brings you closer to more customers

Consumers want reduced sodium & clean labels

**Current Market Size**

**\$1.6 B**

Global Sodium Reduction Market

<sup>1</sup> <https://www.globenewswire.com/news-release/2022/06/13/2460865/0/en/Salt-Substitute-Market-to-Garner-2-3-billion-Globally-By-2030-at-7-9-CAGR-Says-The-Brainy-Insights.html>

# MICROSALT®

**50% LESS SODIUM**

**MICROSALT**  
Full Flavor, Less Sodium

**SALT**

This salt does not supply iodide, a necessary nutrient.

NET WT 2oz (57g) 148mg SODIUM 65% DV

**Nutrition Facts**  
89 servings per container  
**Serving Size** 1/4 tspn (1g)

Amount per serving		% Daily Value*
<b>Calories</b>	<b>0</b>	
<b>Total Fat</b> 0g		0%
Saturated Fat 0g		0%
Trans Fat 0g		
<b>Cholesterol</b> 0mg		0%
<b>Sodium</b> 230mg		10%
<b>Total Carbohydrate</b> 0g		0%
Dietary Fiber 0g		0%
Total Sugars 0g		
Includes 0g Added Sugars		0%
<b>Protein</b> 0g		
Vitamin D 0mcg		0%
Calcium 0mg		0%
Iron 0mg		0%
Potassium 0mg		0%

\*The % Daily Value (DV) tells you how much a nutrient in a serving of food contributes to a daily diet. 2,000 calories a day is used for general advice.



**Kroger**

**FIND SALTME!® IN A KROGER NEAR YOU!**

**Salt Me!**  
Full Flavor, Less Sodium





## SUMMARY

1

Tekcapital commercialises university innovations for its own portfolio and as a service for university clients.

2

We have built a high-value portfolio consisting of Belluscura, Lucyd, Salarius & Guident, all addressing \$B+ markets with exciting near-term growth prospects.

3

Tekcapital has a proven, multi-year track record of transforming university discoveries into valuable, needed products whilst delivering significant growth of NAV and returns on invested capital.